Targeting Parkinson's Disease 2012

Novel approaches to Targeting Parkinson’s Disease include a stronger understanding of LRRK2 biology and potential for compound targeting, identification of novel molecular targets for both disease modification and symptom treatment, like PD-LIDS. Improved biomarker discovery is also needed. Join leading PD researchers from pharma, biotech and non-profit organizations to discuss what the future of PD drug discovery will look like and how we’ll get there.